Equities research analysts predict that Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) will announce ($1.53) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Madrigal Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.74) and the highest estimate coming in at ($1.33). Madrigal Pharmaceuticals reported earnings per share of ($0.75) in the same quarter last year, which would indicate a negative year over year growth rate of 104%. The company is expected to issue its next quarterly earnings results on Wednesday, February 26th.
On average, analysts expect that Madrigal Pharmaceuticals will report full year earnings of ($5.10) per share for the current year, with EPS estimates ranging from ($5.39) to ($4.44). For the next financial year, analysts forecast that the firm will report earnings of ($6.79) per share, with EPS estimates ranging from ($8.22) to ($5.22). Zacks’ EPS averages are a mean average based on a survey of research firms that follow Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.03. During the same quarter last year, the business posted ($0.56) earnings per share.
Several hedge funds have recently modified their holdings of MDGL. Tower Research Capital LLC TRC bought a new stake in shares of Madrigal Pharmaceuticals in the third quarter valued at approximately $41,000. Captrust Financial Advisors bought a new position in Madrigal Pharmaceuticals during the second quarter worth $163,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at $215,000. Metropolitan Life Insurance Co NY raised its stake in Madrigal Pharmaceuticals by 17.9% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 2,668 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 406 shares during the last quarter. Finally, Stanley Laman Group Ltd. acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at $256,000. Institutional investors own 62.15% of the company’s stock.
Shares of NASDAQ:MDGL opened at $113.77 on Friday. The stock has a market capitalization of $1.71 billion, a PE ratio of -51.25 and a beta of 1.15. Madrigal Pharmaceuticals has a 1 year low of $82.31 and a 1 year high of $148.18. The firm has a fifty day moving average price of $98.47 and a 200 day moving average price of $95.70.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Recommended Story: What causes a stock to be most active?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.